SNAP Biosciences licenses Monarch's cell therapy tech

SNAP Biosciences licenses Monarch's cell therapy tech#SNAP #Biosciences #licenses #Monarch039s #cell #therapy #tech

Fractyl Health Unveils New Rejuva ® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Fractyl Health Unveils New Rejuva ® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency…

Spur Therapeutics reports progress in gene therapy trials

Spur Therapeutics reports progress in gene therapy trials#Spur #Therapeutics #reports #progress #gene #therapy #trials

Plus Therapeutics reports progress in CNS cancer therapy

Plus Therapeutics reports progress in CNS cancer therapy#Therapeutics #reports #progress #CNS #cancer #therapy

Apple Music introduces Sound Therapy, songs for focusing, relaxing and sleep

Apple Music is introducing a new “audio wellness” collection of songs called Sound Therapy. Designed in…

Regenxbio stock rises on FDA's priority review for MPS II therapy

Regenxbio stock rises on FDA's priority review for MPS II therapy#Regenxbio #stock #rises #FDA039s #priority #review…

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated…

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst: Strong Opportunity For A Double With A Proven Therapy #BioCryst #Strong #Opportunity #Double #Proven #Therapy

KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally

KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free…

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 #Neurocrine #Biosciences #Valbenazine #Adjunctive #Therapy…

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 #uniQure #Bullish #NearTerm #Catalysts #Breakthrough…

UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington’s Disease Treatment

As of this writing, UniQure N.V.’s stock price has surged 35.89% to $12.79 per share after…

Genflow Biosciences enters AI gene therapy research deal

Genflow Biosciences enters AI gene therapy research deal#Genflow #Biosciences #enters #gene #therapy #research #deal

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space #Solid #Biosciences…

Vertex Pharmaceuticals: A Look At Their Pain Therapy Program

Vertex Pharmaceuticals: A Look At Their Pain Therapy Program #Vertex #Pharmaceuticals #Pain #Therapy #Program

New gene therapy and SPAC merger up big today

*Together with TheSteadyTrader & The Opportunistic Trader Happy Tuesday, 360 – Here are some of our…

FDA fast tracks NKGen's Alzheimer's therapy troculeucel

FDA fast tracks NKGen's Alzheimer's therapy troculeucel#FDA #fast #tracks #NKGen039s #Alzheimer039s #therapy #troculeucel

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory…

CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO…

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success #Sana #Biotechnology #Stock #Price #Rise…

Galapagos Stock Struggles To Carve A Path In A Crowded CAR-T Therapy Market (NASDAQ:GLPG)

This article was written by Follow I’m a stock analyst with an MBA and a background…